Is Liver Transplant or Resection Better for Early HCC?
At a Glance
Early HCC treatment depends on tumor features, liver function, portal hypertension, and overall health. Transplant treats the tumor and cirrhotic liver but requires a donor and lifelong anti-rejection drugs; resection is immediate but leaves the diseased liver, so recurrence remains possible.
In this answer
4 sections
If your hepatocellular carcinoma (HCC) is caught early, deciding how to treat it requires a careful evaluation by a multidisciplinary team. The two main surgical options are surgical resection (removing part of the liver) and a liver transplant (replacing the entire liver). While surgical resection removes the tumor immediately, it leaves the rest of your diseased liver behind, meaning new tumors could form later [1]. A liver transplant removes both the tumor and the underlying diseased liver, which may offer the best chance of long-term disease control for selected patients [2].
Neither operation guarantees a permanent cure, and the right choice depends heavily on your overall liver health, tumor characteristics, and whether you have portal hypertension [3]. Note that for some small tumors, localized ablation (destroying the tumor with heat or cold) can also be a potentially curative first-line option [2].
Surgical Resection: Immediate Tumor Removal
Surgical resection (also called partial hepatectomy) involves cutting out the tumor and a margin of healthy tissue around it.
This option is typically considered for patients who have a single tumor, excellent liver function, and a healthy volume of remaining liver tissue (known as the future liver remnant) [2][4]. Doctors look beyond just a basic “Child-Pugh A” score; they ensure you have normal bilirubin levels, no fluid in the abdomen (ascites), and no significant portal hypertension before recommending surgery [2].
- The advantages: Resection removes the cancer immediately without the need to wait for a donor organ, and you will not need to take lifelong immunosuppressive drugs [5].
- The disadvantages and risks: Surgery carries risks such as bleeding, bile leaks, and post-hepatectomy liver failure [6]. Furthermore, because the rest of your liver is still cirrhotic (scarred), it remains an environment where new cancer cells can easily grow. Recurrence after resection is common, and it usually happens within the liver itself [1].
Liver Transplant: Treating the Liver and the Cancer
A liver transplant involves removing your entire liver and replacing it with a healthy donor liver.
- The advantages: It treats both the cancer and the underlying liver disease (cirrhosis), which generally provides lower recurrence rates than resection [7][8].
- The disadvantages and risks: You must wait for an organ to become available, during which the cancer could grow [7]. Transplant is a major surgery with risks of rejection and infection. You will also require lifelong immunosuppressive medication, which can increase the risk of kidney issues, diabetes, and other cancers over time [5].
To be eligible for a transplant, your cancer must typically meet the Milan criteria. You meet these criteria if you have one tumor that is 5 centimeters or smaller, or up to 2-3 tumors that are each 3 centimeters or smaller, with no cancer invading the major blood vessels (macrovascular invasion) and no spread outside the liver [9][10]. Meeting these criteria makes you eligible, but transplant centers also consider your overall health, tumor markers (like AFP), and sometimes your response to other treatments [11].
The Role of Portal Hypertension
A major factor in deciding between resection and transplant is whether you have clinically significant portal hypertension (CSPH)—high blood pressure in the main vein leading to your liver [3]. Doctors may suspect CSPH if you have enlarged veins in your esophagus (varices), fluid in your abdomen (ascites), or an enlarged spleen with a low platelet count.
When cirrhosis causes severe scarring, blood cannot flow easily, increasing pressure in this vein. If you have CSPH, removing a piece of the liver through resection increases the risk of severe complications, liver failure, and death after surgery [3][12]. For this reason, if you have early-stage cancer and CSPH, a liver transplant is often considered the safer long-term choice [2][13]. However, CSPH is not an absolute barrier to resection; highly selected patients can still safely undergo limited resection at experienced specialty centers [14].
Next Steps and Ongoing Care
If you are placed on the transplant waitlist, your care team may use bridging therapies (like localized ablation) to keep the tumor from growing while you wait [15].
Regardless of which treatment you choose, ongoing care is vital. You will need regular surveillance imaging and blood tests to monitor for recurrence. Additionally, treating the underlying cause of your cirrhosis—such as taking antiviral medications to cure Hepatitis C—remains a critical part of your long-term health plan to protect your new or remaining liver.
Common questions in this guide
How do doctors choose between liver transplant and resection for early HCC?
Is a liver transplant better than surgical resection for early liver cancer?
What are the Milan criteria for a liver transplant?
How does portal hypertension change the choice between resection and transplant?
What treatment can I receive while waiting for a liver transplant?
Can ablation be a first treatment for a small HCC?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my tumor meet the Milan criteria, and what is my expected wait time for a transplant at this center?
- 2.Do I have signs of clinically significant portal hypertension (such as low platelets or varices), and how does that affect my surgical risks?
- 3.Are my bilirubin levels, Child-Pugh score, and estimated future liver remnant sufficient for a safe surgical resection?
- 4.Would localized ablation be a better or equally effective first-line option for my specific tumor?
- 5.If I go on the transplant list, what 'bridging' treatments will we use to keep the cancer from growing while I wait?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.
Xu XF, Xing H, Han J, et al.
JAMA surgery 2019; (154(3)):209-217 doi:10.1001/jamasurg.2018.4334.
PMID: 30422241 - 2
Assessing the Validity of the AASLD Surgical Treatment Algorithm in Patients with Early-Stage Hepatocellular Carcinoma.
Kim A, Song BG, Kang W, et al.
Gut and liver 2025; (19(2)):265-274 doi:10.5009/gnl240214.
PMID: 39930622 - 3
Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J, Zhang H, Xia Y, et al.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(1)):1-13 doi:10.1016/j.hpb.2018.07.005.
PMID: 30082213 - 4
Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines.
Manzini G, Henne-Bruns D, Porzsolt F, Kremer M
BMJ open gastroenterology 2017; (4(1)):e000129 doi:10.1136/bmjgast-2016-000129.
PMID: 28405349 - 5
Surgical treatments for early-stage hepatocellular carcinoma: Resection versus transplantation.
Kokudo T, Yamaguchi T, Halkic N, Kokudo N
Global health & medicine 2025; (7(6)):414-415 doi:10.35772/ghm.2025.01133.
PMID: 41488208 - 6
Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma.
Citterio D, Facciorusso A, Sposito C, et al.
JAMA surgery 2016; (151(9)):846-53 doi:10.1001/jamasurg.2016.1121.
PMID: 27248425 - 7
The Treatment Effect of Liver Transplantation versus Liver Resection for HCC: A Review and Future Perspectives.
Beumer BR, de Wilde RF, Metselaar HJ, et al.
Cancers 2021; (13(15)) doi:10.3390/cancers13153730.
PMID: 34359629 - 8
Oncological Outcomes of Hepatic Resection vs Transplantation for Localized Hepatocellular Carcinoma.
Akcam AT, Saritas AG, Ulku A, Rencuzogullari A
Transplantation proceedings 2019; (51(4)):1147-1152 doi:10.1016/j.transproceed.2019.01.093.
PMID: 31101189 - 9
Surgical treatment of hepatocellular carcinoma.
Sugawara Y, Hibi T
Bioscience trends 2021; (15(3)):138-141 doi:10.5582/bst.2021.01094.
PMID: 33746184 - 10
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
Llovet JM, Pavel M, Rimola J, et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018; (24(3)):369-379 doi:10.1002/lt.24977.
PMID: 29140601 - 11
Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.
Alim A, Erdogan Y, Dayangac M, et al.
Cancer control : journal of the Moffitt Cancer Center 2021; (28()):10732748211011960 doi:10.1177/10732748211011960.
PMID: 33926242 - 12
Impact and outcomes of liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.
Cortese S, Tellado JM
Cirugia y cirujanos 2022; (90(5)):579-587 doi:10.24875/CIRU.22000041.
PMID: 36327469 - 13
Hepatocellular carcinoma.
Forner A, Reig M, Bruix J
Lancet (London, England) 2018; (391(10127)):1301-1314 doi:10.1016/S0140-6736(18)30010-2.
PMID: 29307467 - 14
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.
Azoulay D, Ramos E, Casellas-Robert M, et al.
JHEP reports : innovation in hepatology 2021; (3(1)):100190 doi:10.1016/j.jhepr.2020.100190.
PMID: 33294830 - 15
Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND, Waljee AK, Singal AG
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2015; (21(9)):1142-52 doi:10.1002/lt.24169.
PMID: 25981135
This comparison is for informational purposes only and is not medical advice. Your liver, transplant, and cancer specialists can recommend the safest option based on your tumor, liver function, portal hypertension, and overall health.
Get notified when new evidence is published on Adult hepatocellular carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.